{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:37:47Z","timestamp":1790087867100,"version":"4.0.1"},"reference-count":26,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["269864"],"award-info":[{"award-number":["269864"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["2019105"],"award-info":[{"award-number":["2019105"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["269864"],"award-info":[{"award-number":["269864"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2019105"],"award-info":[{"award-number":["2019105"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Previous studies have indicated elevated levels of impulsivity, hyperactivity, and inattention (IHI) among opioid-dependent patients seeking outpatient treatment with extended-release naltrexone (XR-NTX). This led us to hypothesize that IHI may be associated with a higher discontinuation rate for XR-NTX treatment. In a group of 162 patients with opioid dependence, discontinuation prior to the full 24 weeks of the study period (six injections and attending the study visit at 24 weeks) occurred in 49% of the patients, primarily in the early stage of treatment. IHI above the clinical cut-off on the adult ADHD self-report scale (ASRS) was not associated with a risk of premature discontinuation. This finding was not altered when controlling for socio-demographics, substance, use and mental health severity. Conclusively, high levels of IHI per se is not contradictive for XR-NTX treatment in regard to concern for premature discontinuation.<\/jats:p>","DOI":"10.3390\/ijerph191811435","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T22:53:46Z","timestamp":1663023226000},"page":"11435","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-2389","authenticated-orcid":false,"given":"Ann Tarja","family":"Karlsson","sequence":"first","affiliation":[{"name":"Addiction Unit, S\u00f8rlandet Hospital HF, 4604 Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5480","authenticated-orcid":false,"given":"John-K\u00e5re","family":"Vederhus","sequence":"additional","affiliation":[{"name":"Addiction Unit, S\u00f8rlandet Hospital HF, 4604 Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Clausen","sequence":"additional","affiliation":[{"name":"Addiction Unit, S\u00f8rlandet Hospital HF, 4604 Kristiansand, Norway"},{"name":"Norwegian Centre for Addiction Research, University of Oslo, 0315 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Weimand","sequence":"additional","affiliation":[{"name":"Center for Mental Health and Substance Abuse, University of South-Eastern Norway, 3040 Drammen, Norway"},{"name":"Department of R&D in Psychiatric Health Care, Akershus University Hospital, 1478 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-2947","authenticated-orcid":false,"given":"Kristin Klemmetsby","family":"Solli","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research, University of Oslo, 0315 Oslo, Norway"},{"name":"Department of R&D in Psychiatric Health Care, Akershus University Hospital, 1478 Oslo, Norway"},{"name":"Vestfold Hospital Trust, 3103 T\u00f8nsberg, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[{"name":"Department of R&D in Psychiatric Health Care, Akershus University Hospital, 1478 Oslo, Norway"},{"name":"Faculty for Health Science, Oslo Metropolitan University, 0130 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: Implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci. Pract. Perspect"},{"key":"ref_2","first-page":"249","article-title":"A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?","volume":"29","author":"Biondi","year":"2020","journal-title":"Am. J. Addict.\/Am. Acad. Psychiatr. Alcohol. Addict."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J. Addict. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL(R)): A review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1369-1600.2007.00067.x","article-title":"Does naltrexone affect craving in abstinent opioid-dependent patients?","volume":"12","author":"Dijkstra","year":"2007","journal-title":"Addict. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108667","DOI":"10.1016\/j.jsat.2021.108667","article-title":"\u2018Not at all what I had expected\u2019: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study","volume":"136","author":"Brenna","year":"2022","journal-title":"J. Subst. Abuse Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000501931","article-title":"Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial","volume":"25","author":"Solli","year":"2019","journal-title":"Eur. Addict. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cpr.2013.07.007","article-title":"Drop-out from addiction treatment: A systematic review of risk factors","volume":"33","author":"Brorson","year":"2013","journal-title":"Clin. Psychol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Karlsson, A.T., Vederhus, J.K., Clausen, T., Weimand, B., Solli, K.K., and Tanum, L. (2021). Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194558"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100728","DOI":"10.1016\/j.conctc.2021.100728","article-title":"Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study)","volume":"21","author":"Weimand","year":"2021","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"ref_14","unstructured":"American Psychiatric, A. (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing, Inc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0033291704002892","article-title":"The World Health Organization adult ADHD self-report scale (ASRS): A short screening scale for use in the general population","volume":"35","author":"Kessler","year":"2005","journal-title":"Psychol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/08039480310000932","article-title":"Measuring the mental health status of the Norwegian population: A comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36)","volume":"57","author":"Strand","year":"2003","journal-title":"Nord. J. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000259089","article-title":"EuropASI: European Adaptation of a Multidimensional Assessment Instrument for Drug and Alcohol Dependence","volume":"1","author":"Kokkevi","year":"1995","journal-title":"Eur. Addict. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108686","DOI":"10.1016\/j.jsat.2021.108686","article-title":"Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data","volume":"136","author":"Zhang","year":"2022","journal-title":"J. Subst. Abuse Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108183","DOI":"10.1016\/j.jsat.2020.108183","article-title":"Patients\u2019 perspectives on initiating treatment with extended-release naltrexone (XR-NTX)","volume":"122","author":"Gauthier","year":"2021","journal-title":"J. Subst. Abuse Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.addbeh.2014.05.007","article-title":"Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study","volume":"39","author":"Bukten","year":"2014","journal-title":"Addict. Behav."},{"key":"ref_24","first-page":"319","article-title":"Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders","volume":"26","author":"Williams","year":"2017","journal-title":"Am. J. Addict.\/Am. Acad. Psychiatr. Alcohol. Addict."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugalcdep.2018.02.018","article-title":"Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications","volume":"187","author":"Muller","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/18\/11435\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:30Z","timestamp":1760142570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/18\/11435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,11]]},"references-count":26,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijerph191811435"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191811435","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,11]]}}}